GlassScriptPhysician profile
Gary M Goodman
NPI 1811999485
$53,947.89
in general payments reported to CMS, 2019-2025
34 companies · $1,860 in 2025
The $1,860 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $10K · 2021: $701 · 2022: $1,122 · 2023: $1,419 · 2024: $1,629 · 2025: $1,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,757 · Education: $129 · Consulting Fee: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,756.77 |
| Education | $128.99 |
| Consulting Fee | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $47,143.90 | 2019-2020 | |
| Glaxosmithkline, LLC. | $1,678.78 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,079.05 | 2020-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $616.29 | 2022-2025 | Dupixent |
| Csl Behring | $460.00 | 2021-2025 | Hizentra, Andembry, Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $398.92 | 2023-2025 | Cuvitru, Hyqvia, Eohilia |
| Genzyme Corporation | $347.65 | 2021-2025 | |
| Optinose US, INC. | $282.28 | 2020-2025 | |
| Grifols USA, LLC | $263.60 | 2020-2025 | Xembify |
| Genentech USA, INC. | $210.77 | 2021-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $187.12 | 2024-2025 | |
| Pfizer INC. | $184.45 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $165.30 | 2021 | |
| Kaleo, INC. | $119.70 | 2021-2023 | Auvi-Q |
| Abbvie INC. | $96.28 | 2023-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $94.99 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $75.20 | 2025 | Neffy |
| Amgen INC. | $71.00 | 2025 | Tezspire |
| Kedrion Biopharma, INC. | $62.46 | 2024-2025 | Albuked, Gammaked, Rhogam Ultra-Filtered Plus |
| Blueprint Medicines Corporation | $55.52 | 2023-2024 | Ayvakit |
| Hikma Pharmaceuticals USA | $47.50 | 2023-2025 | Ryaltris |
| Bio Products Laboratory USA, INC. | $43.84 | 2023 | Coagadex, Gammaplex |
| Eyevance Pharmaceuticals LLC | $43.09 | 2021 | |
| Gc Biopharma USA, INC. | $35.26 | 2025 | Alyglo |
| Lilly USA, LLC | $31.27 | 2025 | Ebglyss, Taltz, Zepbound |
| Adma Biomanufacturing LLC | $23.10 | 2025 | |
| Leo Pharma INC. | $21.13 | 2025 | Anzupgo |
| Cycle Pharmaceuticals INC | $18.71 | 2025 | Sajazir |
| Biocryst US Sales Co., LLC | $18.12 | 2022 | |
| Merck Sharp & Dohme LLC | $16.61 | 2021 | |
| Azurity Pharmaceuticals, INC. | $15.99 | 2025 | Alvesco |
| Paratek Pharmaceuticals, INC. | $14.52 | 2025 | Xhance |
| Aimmune Therapeutics, INC. | $14.41 | 2022 | |
| Mylan Specialty L.P. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.